The price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $11.22 in the last session, up 4.08% from day before closing price of $10.78. In other words, the price has increased by $+0.44 from its previous closing price. On the day, 11162805 shares were traded.
Ratios:
We take a closer look at RXRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.70 and its Current Ratio is at 4.70. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 13 ’24 when Secora Michael sold 25,000 shares for $11.03 per share. The transaction valued at 275,815 led to the insider holds 1,204,179 shares of the business.
Secora Michael sold 25,000 shares of RXRX for $261,375 on Mar 12 ’24. The Chief Financial Officer now owns 1,191,679 shares after completing the transaction at $10.46 per share. On Mar 06 ’24, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 36,319 shares for $11.86 each. As a result, the insider received 430,682 and left with 1,108,524 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2.64B and an Enterprise Value of 2.29B. For the stock, the TTM Price-to-Sale (P/S) ratio is 54.32 while its Price-to-Book (P/B) ratio in mrq is 5.66. Its current Enterprise Value per Revenue stands at 52.29 whereas that against EBITDA is -7.46.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $16.75, while it has fallen to a 52-week low of $4.54. The 50-Day Moving Average of the stock is 11.29, while the 200-Day Moving Average is calculated to be 9.25.
Shares Statistics:
According to the various share statistics, RXRX traded on average about 6.90M shares per day over the past 3-months and 6.94M shares per day over the past 10 days. A total of 226.26M shares are outstanding, with a floating share count of 146.52M. Insiders hold about 32.10% of the company’s shares, while institutions hold 77.28% stake in the company. Shares short for RXRX as of Feb 29, 2024 were 42.82M with a Short Ratio of 6.21, compared to 38.27M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 18.25% and a Short% of Float of 27.40%.
Earnings Estimates
The company has 6 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.43 for the current quarter, with a high estimate of -$0.39 and a low estimate of -$0.48, while EPS last year was -$0.34. The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.38 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.49 and -$2.1 for the fiscal current year, implying an average EPS of -$1.73. EPS for the following year is -$1.89, with 7 analysts recommending between -$1.12 and -$3.5.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $13.07M. It ranges from a high estimate of $20.8M to a low estimate of $10M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $12.13M, an estimated increase of 7.70% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $13.58M, an increase of 23.30% over than the figure of $7.70% in the same quarter last year. There is a high estimate of $20.8M for the next quarter, whereas the lowest estimate is $10.9M.
A total of 7 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $83.3M, while the lowest revenue estimate was $43M, resulting in an average revenue estimate of $57.3M. In the same quarter a year ago, actual revenue was $44.58M, up 28.50% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $86.8M in the next fiscal year. The high estimate is $254.9M and the low estimate is $30.52M. The average revenue growth estimate for next year is up 51.50% from the average revenue estimate for this year.
